FIELD: chemistry.
SUBSTANCE: invention relates to molecular pharmacology and particularly to a peptide which is an interleukin-15 (IL-15) sequence derivative which is optimised for inhibiting biological activity of said compound. The invention shows that when bound with an alpha subunit of the receptor (IL-15Rα) the peptide inhibits T cell proliferation induced by IL-15, tumour necrosis factor α (TNFα) induction caused by IL-15, and expression of IL-8 and IL-6 caused by IL-15Rα. The invention also relates to use of the peptide in treating pathologies where anomalous expression of IL-15 or IL-15Rα is associated with the course of a disease such as rheumatoid arthritis (AR) and prostate cancer.
EFFECT: obtaining an interleukin-15 (IL-15) sequence derivative which is optimised for inhibiting biological activity of said compound.
18 cl, 6 dwg, 6 ex
| Title | Year | Author | Number |
|---|---|---|---|
| INTERLEUKINE-15 PEPTIDE ANTAGONIST | 2005 |
|
RU2396276C2 |
| VACCINE COMPOSITION CONTAINING MUTANT HUMAN INTERLEUKIN-15 | 2017 |
|
RU2745199C2 |
| COMPOSITIONS AND METHOD FOR IMMUNOSUPPRESSION | 2001 |
|
RU2270691C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-R[ALPHA] SUSHI DOMAIN | 2012 |
|
RU2644671C2 |
| RECOMBINANT CHIMERIC PROTEIN ANTH1, NUCLEIC ACID ENCODING ITS AND THEIR USING | 2003 |
|
RU2322455C2 |
| INTERLEUKIN 15 PROTEIN COMPLEX AND USE THEREOF | 2015 |
|
RU2711979C2 |
| BIOLOGICALLY ACTIVATED DRUGS BASED ON CYTOKINES AND METHODS OF USING THEM | 2019 |
|
RU2819307C2 |
| HETERODIMERIC IL-15 PROTEIN AND USE THEREOF | 2014 |
|
RU2689717C2 |
| IMMUNOCYTOKINES BASED ON IL-15 AND IL-15Rα OF THE SUSHI DOMAIN | 2012 |
|
RU2763298C2 |
| METHOD FOR PURIFYING CONJUGATES BASED ON IL-15/IL-15Rα | 2015 |
|
RU2701301C2 |
